Reuters Legal & Pharma Intelligence Feed

Entresto Patent Defense & Generic Entry Analyzer

Ground-truth pharmaceutical patent litigation workbench evaluating Novartis's Entresto (sacubitril/valsartan) supramolecular co-crystal complex patent defense against generic challengers across the UK High Court, EPO, and US courts.

Litigation Status (UK High Court)
UPHELD
Co-crystal inventive step validated
Exclusivity Extension
+36 Months
Market protected through Nov 2026
Protected UK/EU Revenue
$4.35B
Avoided generic price cliff erosion
Defense Strength Index
88 / 100
Supramolecular synergy proof
Patent Exclusivity & Litigation Milestones Timeline Years 2020 – 2028
Commercial Revenue Trajectory: Upheld Patent vs. Generic Cliff Erosion Millions USD / Year
Entresto Patent Claim Portfolio Defense Matrix Patent Thicket Anatomy
Patent Identifier Claim Subject Matter Core Expiry Defense Argument Court Viability
Enjoy this tool? Build your own with Super